---
title: "Vesugen"
canonical_url: https://peptidelibrary.app/library/vesugen
description: "Lys-Glu-Asp, a synthetic tripeptide in the Khavinson bioregulator series associated with vascular tissue and endothelial function. It is distinct from Ventfort, the tissue extract marketed for the same purpose. The proposed activity rests on cell-culture and cytogenetic work from one research group published mainly in Russian, without independent replication or controlled human evidence. Not FDA-approved."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Vesugen

Vesugen (also called Lys-Glu-Asp or Vascular bioregulator) is a khavinson vascular tripeptide in the Short Peptide Bioregulator class. Vesugen is Lys-Glu-Asp, a synthetic tripeptide in the Khavinson series associated with vascular tissue.

Lys-Glu-Asp, a synthetic tripeptide in the Khavinson bioregulator series associated with vascular tissue and endothelial function. It is distinct from Ventfort, the tissue extract marketed for the same purpose. The proposed activity rests on cell-culture and cytogenetic work from one research group published mainly in Russian, without independent replication or controlled human evidence. Not FDA-approved.

Also known as: Lys-Glu-Asp, Vascular bioregulator.

Categories: Muscle/Recovery, Experimental.

## Classification

- Type: Khavinson vascular tripeptide / research
- Mechanism class: Short Peptide Bioregulator
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Vesugen is Lys-Glu-Asp, a synthetic tripeptide in the Khavinson series associated with vascular tissue. The series hypothesis proposes that such peptides enter the nucleus and interact with specific promoter sequences to influence transcription of tissue-relevant genes, with reported effects here on endothelial cell protein synthesis and vascular wall markers. The evidence consists of cell-culture and cytogenetic studies from one research group published mainly in Russian; there is no independent replication, no characterised receptor, and no modern randomised controlled trial evidence for vascular outcomes.

Targets: Vascular endothelium (proposed).

Origin: Synthetic short peptide.

## Properties

- Sequence: Lys Glu Asp (KED)
- Molecular formula: C15H26N4O8
- Molecular weight: ≈390.4 g/mol
- CAS number: 204271-66-9
- Half-life: Not established (limited public PK data; primarily research context)

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Early or uncontrolled human studies
- Human trials: 4
- Controlled human trials: 0
- Preclinical sources: 0
- Latest source: 2016

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. [The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people]. Adv Gerontol. 2014. 2014. Human study (early or uncontrolled). Population: Patients with vasculogenic erectile dysfunction linked to atherosclerosis (n=41). Better blood flow in the main penile arteries after treatment, by clinical and instrument measures [Source](https://pubmed.ncbi.nlm.nih.gov/25051774/)
2. [Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission]. Adv Gerontol. 2015. 2015. Human study (early or uncontrolled). Population: Adults aged 41–83 with several chronic illnesses and organic brain syndrome in remission (n=32). The authors report slower biological ageing by their markers, stronger with vesugen; a fall in blood CD34+ cells and a pro-oxidant effect were also seen [Source](https://pubmed.ncbi.nlm.nih.gov/26390612/)
3. [Comparative analysis of different methods of geroprotective]. Adv Gerontol. 2016. 2016. Human study (early or uncontrolled). Population: Patients of different ages (n=110 across all methods). The largest change in biological-age markers was reported for vesugen and pinealon combined [Source](https://pubmed.ncbi.nlm.nih.gov/28539017/)
4. The peptide correction of neurotic disorders among professional truck-drivers. Adv Gerontol. 2012. 2012. Human study (early or uncontrolled). Population: Male truck drivers, with metal craftsmen as a comparison group (n=300). Psychoemotional and stress-resistance measures; the best effect was reported for pinealon combined with vesugen [Source](https://pubmed.ncbi.nlm.nih.gov/23734521/)

## Safety

Side effects: Not characterized.

Risks: Research-only.

Human safety basis: Limited human reports

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

Vesugen is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is Vesugen?

Lys-Glu-Asp, a synthetic tripeptide in the Khavinson bioregulator series associated with vascular tissue and endothelial function. It is distinct from Ventfort, the tissue extract marketed for the same purpose. The proposed activity rests on cell-culture and cytogenetic work from one research group published mainly in Russian, without independent replication or controlled human evidence. Not FDA-approved.

### How does Vesugen work?

Vesugen is Lys-Glu-Asp, a synthetic tripeptide in the Khavinson series associated with vascular tissue. The series hypothesis proposes that such peptides enter the nucleus and interact with specific promoter sequences to influence transcription of tissue-relevant genes, with reported effects here on endothelial cell protein synthesis and vascular wall markers.

### Is Vesugen FDA approved?

No. Vesugen is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of Vesugen?

Reported half-life for Vesugen is Not established (limited public PK data; primarily research context). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of Vesugen?

Vesugen has the sequence Lys Glu Asp (KED). Its molecular formula is C15H26N4O8.

### What peptides are similar to Vesugen?

Compounds most often compared with Vesugen include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [\[Prospects for use of short peptides in pharmacotherapeutic correction of Alzheimer's disease.\] — Adv Gerontol, 2024](https://pubmed.ncbi.nlm.nih.gov/38944767/)
- [Effect of tripeptide Lys-Glu-Asp on physiological activity of neuroimmunoendocrine system cells — Bull Exp Biol Med, 2012](https://pubmed.ncbi.nlm.nih.gov/22977872/)
- [Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease — Bull Exp Biol Med, 2021](https://pubmed.ncbi.nlm.nih.gov/34173097/)
- [\[The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people\] — Adv Gerontol, 2014](https://pubmed.ncbi.nlm.nih.gov/25051774/)
